Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AGN-199201 Dose A · 1 trial · 2 indications
Percentage of participants with at least a 2-grade decrease from Baseline (Improvement) in the CEA score and at least a 2-grade decrease from Baseline (Improvement) in the SSA score were assessed on Day 28 hours 2 to 12. The investigator evaluated the severity of the participant's erythema (redness of the skin) as measured by the CEA using a 5-point scale where 0=clear skin with no signs of erythema; 1=almost clear of erythema, slight redness; 2=mild erythema, definite redness; 3=moderate erythema, marked redness and 4=severe erythema, fiery redness. The participant assessed the severity of their erythema as measured by the SSA using a 5-point scale where 0=clear of unwanted redness; 1=nearly clear of unwanted redness; 2=somewhat more redness than I prefer; 3=more redness than I prefer and 4=completely unacceptable redness.
| Arm | Type | Description |
|---|---|---|
| AGN-199201 Dose A Once Daily | EXPERIMENTAL | AGN-199201 Dose A applied once daily to the face for 28 days. |
| AGN-199201 Dose B Once Daily | EXPERIMENTAL | AGN-199201 Dose B applied once daily to the face for 28 days. |
| AGN-199201 Dose C Once Daily | EXPERIMENTAL | AGN-199201 Dose C applied once daily to the face for 28 days. |
| AGN-199201 Vehicle Once Daily | PLACEBO_COMPARATOR | AGN-199201 Vehicle applied once daily to the face for 28 days. |
| AGN-199201 Dose A Twice Daily | EXPERIMENTAL | AGN-199201 Dose A applied twice daily to the face for 28 days. |
| AGN-199201 Dose B Twice Daily | EXPERIMENTAL | AGN-199201 Dose B applied twice daily to the face for 28 days. |
| AGN-199201 Dose C Twice Daily | EXPERIMENTAL | AGN-199201 Dose C applied twice daily to the face for 28 days. |
| AGN-199201 Vehicle Twice Daily | PLACEBO_COMPARATOR | AGN-199201 Vehicle applied twice daily to the face for 28 days. |
| Name | Type | Description |
|---|---|---|
| AGN-199201 Dose A | DRUG | AGN-199201 Dose A applied once or twice daily to the face for 28 days. |
| AGN-199201 Dose B | DRUG | AGN-199201 Dose B applied once or twice daily to the face for 28 days. |
| AGN-199201 Dose C | DRUG | AGN-199201 Dose C applied once or twice daily to the face for 28 days. |
| AGN-199201 Vehicle | DRUG | AGN-199201 Vehicle applied once or twice daily to the face for 28 days. |
Inclusion Criteria: * Redness of the skin caused by rosacea Exclusion Criteria: * ≥3 inflammatory lesions * Laser light-source or other energy based therapy in the last 6 months * Any prescription or over the counter product for the treatment of acne or rosacea in the last 14 days
AGN-199201 Dose A is an investigational small molecule being studied for the treatment of erythema associated with rosacea, a chronic skin condition. It is in Phase 2 clinical development and is being evaluated in patients with rosacea and erythema.
AGN-199201 Dose A is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The company is conducting clinical research on this investigational drug for rosacea.
AGN-199201 Dose A is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 2 clinical trial evaluating the drug for erythema with rosacea has been completed.
AGN-199201 Dose A was studied in a completed Phase 2 clinical trial identified as NCT01735201, titled 'AGN-199201 for the Treatment of Erythema With Rosacea.' The trial enrolled 357 participants in the United States and was randomized, double-blind, and placebo-controlled.
Yes, AGN-199201 Dose A is a small molecule drug. It is being developed as a dermatology treatment for rosacea, specifically targeting erythema, which is facial redness associated with the condition.